News
Tofacitinib Slows Joint Damage in Rheumatoid Arthritis
Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
Your search for tofacitinib returned 7 results
ACR/ARHP 2018 Annual Meeting
RA Remission Compared for Tofacitinib Alone vs. Steroid Plus Tofacitinib Tx
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP Annual Meeting 2015
Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA
Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
ACR 2019, News
Few Serious Infections in Offspring Exposed to Non-TNFi Biologics, Tofacitinib
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
ACR/ARHP 2018 Annual Meeting
Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
ACR/ARHP 2018 Annual Meeting
Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
ACR/ARHP 2018 Annual Meeting
CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
